# EternaTear

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eternatear

- Industry: Pharmaceuticals
- Headquarters: Raleigh, US
- Website: www.eternatear.com
- Total disclosed funding: $7.1M
- Latest round: Series A (Oct 7, 2020)
- Investors on record: 6

## About

EternaTear, Inc. specializes in the development of advanced artificial tear solutions aimed at effectively treating dry eye syndrome, offering innovative products that enhance patients' quality of life.EternaTear, Inc. was founded in 2018 and is headquartered in Raleigh, US. The company focuses on creating artificial tear solutions for dry eye syndrome. The founder, Tim W, has a background that includes previous entrepreneurial ventures. EternaTear has successfully raised USD 4.9 mn in its Series A funding round on October 7, 2020, led by Carolina Angel Network and Keiretsu Forum, among other investors. The company has engaged in two funding deals to date, with the most recent round representing the total amount raised.EternaTear™ specializes in developing advanced artificial tear solutions designed to address the complexities of dry eye syndrome. The flagship product, EternaTear™, utilizes a novel mechanism to mimic the composition and function of natural tears, providing longer-lasting relief than conventional over-the-counter eye drops. EternaTear™ targets eye care professionals, patients with moderate to severe dry eye, and organizations seeking effective treatment options, primarily marketed in North America with plans for international expansion.EternaTear™ generates revenue through direct sales of its flagship product, EternaTear™, to healthcare providers and pharmacies that serve patients with dry eye syndrome. The company partners with eye care professionals who recommend the product, facilitating a direct-to-consumer model along with possible wholesale arrangements for broader distribution. The pricing strategy reflects the premium nature of EternaTear™, focusing on its unique benefit of longer-lasting relief compared to traditional artificial tears.EternaTear plans to leverage the USD 4.9 mn raised in the Series A funding round to enhance product development and expand into new markets. The company is designing additional products aimed at further improving dry eye treatment, with details on release dates to be announced. Furthermore, EternaTear intends to penetrate international markets beyond North America, targeting specific regions for expansion by the end of 2023.

## Funding rounds

- Series A, Oct 7, 2020, $4.9M — Band of Angels, Keiretsu Forum, Keiretsu Capital, DeepWork Capital, Carolina Angel Network
- Seed, Apr 9, 2020, $2.2M — MED1 Ventures

## Investors

- MED1 Ventures (https://capitalatlas.ai/funds/med1-ventures) — Seed
- Band of Angels (https://capitalatlas.ai/funds/band-of-angels) — Series A
- Keiretsu Forum — Series A
- Keiretsu Capital (https://capitalatlas.ai/funds/keiretsu-capital) — Series A
- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series A
- Carolina Angel Network (https://capitalatlas.ai/funds/carolina-angel-network) — Series A